about
Linkage of two human pregnancy-specific beta 1-glycoprotein genes: one is associated with hydatidiform molePast, present, and future of hormonal therapy in recurrent endometrial cancerPrediction of chemo-response in serous ovarian cancerTemsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers.Progesterone: the ultimate endometrial tumor suppressor.EGFR isoforms and gene regulation in human endometrial cancer cellsA mechanism for synergy with combined mTOR and PI3 kinase inhibitors."Collection of a lifetime: a practical approach to developing a longitudinal collection of women's healthcare biological samples".Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model.An exploratory study of the variables impacting preterm birth rates in New MexicoTP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.BKCa channel inhibitor modulates the tumorigenic ability of hormone-independent breast cancer cells via the Wnt pathwayA phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.miR-888: A Novel Cancer-Testis Antigen that Targets the Progesterone Receptor in Endometrial Cancer.Genetic Deficiency of Mtdh Gene in Mice Causes Male Infertility via Impaired Spermatogenesis and Alterations in the Expression of Small Non-coding RNAs.A randomized controlled trial of interleukin-1 receptor antagonist in a rabbit model of ascending infection in pregnancyCytoplasmic Metadherin (MTDH) provides survival advantage under conditions of stress by acting as RNA-binding protein.Inverse Relationship between Progesterone Receptor and Myc in Endometrial Cancer.Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activates IGF-1R/PI3K/Akt signalingEffects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance.Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcomaA phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.Chemotherapeutic drugs in pregnancy.Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancermicroRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAsCullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182.Hepatitis B and C in pregnancy: a review and recommendations for care.Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devicesTargeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy.A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group studyThe consequence of oncomorphic TP53 mutations in ovarian cancer.Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group studyIntroduction to the American Heart Association's Hypertension Strategically Focused Research Network.Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations.Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.An inhibitor of K+ channels modulates human endometrial tumor-initiating cells.Role of metadherin in estrogen-regulated gene expression.
P50
Q24557537-F09B2E6D-8BAB-4C6F-8A4D-76A8B4A79324Q26993208-E4D5D3E3-79E2-45A4-BC87-B1FA87630B4BQ29248636-AA7645D6-BBD9-4FA3-AEDF-D5E7E3316894Q30407709-862541A5-EE63-45D5-A67B-D8474EC7E325Q33598887-9CB04BE1-0874-43A1-8BB2-B6B9C1D1368DQ33773307-7E8CCDA2-6DE9-4DFF-8AC3-D00DA3281F54Q34008570-6FBE426A-D86C-47E0-9451-4407D68F3FF9Q34062367-29742212-19EB-42B8-9CD8-F633D925C939Q34103883-2DD3E420-50B5-49A2-94B7-A91C1D92753DQ34173305-17BEC956-E5EF-421B-8BDD-007D4766CEF8Q34312721-F93A8F64-6AEE-45E8-9566-3C85BDF5B8F2Q34775855-E24F741F-7E53-42BE-BE7B-F96A664A95EFQ34781699-290EAD73-0452-410A-AD0E-174EEED95B94Q35012494-3AFB69ED-F8F0-48B5-B335-1C5F37D945B5Q35216723-0A84448D-6550-4F7D-A681-70FC4AB79DF8Q35555424-97356509-F8E3-41A2-9DC7-766E1D319CCEQ35583031-B69996F4-ADD8-4487-9B89-0722988BB138Q35614911-BF25C62D-022B-459C-8AC5-D31C09C43171Q35762980-334FB053-57AD-4ABF-BB4B-0996BC42727FQ35918161-F3F9A484-89E9-4EC4-836C-055CFCBD1281Q35945498-9DF54A87-F979-43F5-90E4-83252FC5FE05Q36101707-1E13C2A1-016A-4D03-96A2-B9A57A78B32BQ36206242-39BF4D2B-BB98-4931-A651-8C05CD05B4EEQ36225204-55471B97-3472-444D-B76D-7C874C685482Q36274386-D96714E5-ACEA-4742-AE99-1FE40ACC4A43Q36323711-22B8EDF9-4DFD-48F0-952A-AC733AB8BCEFQ36456386-F44D71D9-653D-427C-8735-FD7380E08C8DQ36456399-E7DA0AF2-F9A4-4DAB-B4BE-A272C07FD89BQ36641178-9B7F93AE-192D-4C29-95A9-6460DA724794Q36649138-6FB637B8-BAC4-4BBD-98C3-99CED7C941FCQ36669005-02266F8C-B852-4F80-A0B7-01221AA83B84Q36902458-18F6C5E8-3B2B-4F47-9321-07150415D26DQ36980484-62F15B5B-C616-4DF7-AB84-57C5CA0775BDQ37225303-6660D319-F589-47E4-A1E5-1DF7064F31CFQ37429034-D83E4D11-AAF8-4A92-BFE8-B023D3C55CEAQ37469821-7D60F921-50F3-459A-B9A4-893D126F0E7AQ37600696-3A8956FB-BE3E-48D4-9542-1162B49EAD94Q37671783-DA297AD9-4754-4FAC-A966-1A50AD705C05Q38502913-738E7C52-5468-4A93-A83A-87AB7AA89EC1Q38719595-CF6F3AF8-BEA9-46DD-A81E-434840487352
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kimberly K Leslie
@ast
Kimberly K Leslie
@en
Kimberly K Leslie
@es
Kimberly K Leslie
@nl
type
label
Kimberly K Leslie
@ast
Kimberly K Leslie
@en
Kimberly K Leslie
@es
Kimberly K Leslie
@nl
prefLabel
Kimberly K Leslie
@ast
Kimberly K Leslie
@en
Kimberly K Leslie
@es
Kimberly K Leslie
@nl
P106
P1153
7103111922
P21
P31
P496
0000-0002-2704-8990